Valneva Ixiaro travel vaccine explained for U.S. travelers

Valneva Ixiaro is a prescription vaccine used to help protect adults and children from Japanese encephalitis before travel to certain parts of Asia and the Western Pacific. Here is how it works and what U.S. travelers should know.

Valneva Ixiaro Japanese encephalitis vaccine is a prescription shot used to help prevent Japanese encephalitis in adults and children who plan to travel to certain parts of Asia and the Western Pacific where the virus is present FDA, 03/30/2024.

As of: 06/10/2026 | Reading time: approx. 6 minutes

By the AD HOC NEWS editorial team - specialized in product-focused market coverage.

At a Glance

• Product: Valneva Ixiaro Japanese encephalitis vaccine
• Category: Inactivated travel vaccine for Japanese encephalitis
• Brand/Manufacturer: Valneva
• Primary Use Cases: Pre-travel protection against Japanese encephalitis
• Availability: Prescription vaccine via travel clinics and healthcare providers
• Core Markets: Travelers from the US, Europe, and other non-endemic regions to at-risk parts of Asia and the Western Pacific

What Valneva Ixiaro Japanese encephalitis vaccine is and how it works

Valneva Ixiaro Japanese encephalitis vaccine is an inactivated vaccine based on inactivated Japanese encephalitis virus antigen produced in cell culture and formulated with aluminum-based adjuvant, and it is given as an injection into a muscle FDA, 03/30/2024.

The vaccine is designed to stimulate the immune system to produce antibodies against Japanese encephalitis virus, so that the body can respond more effectively if exposed to the virus during travel to risk areas EMA, 04/15/2024.

Japanese encephalitis itself is a viral infection transmitted by mosquitoes in rural and peri-urban areas of parts of Asia and the Western Pacific, and in rare cases it can lead to severe brain inflammation with serious complications CDC, 02/20/2025.

Why Valneva Ixiaro Japanese encephalitis vaccine matters for US consumers and industry

For US travelers, the main relevance of Valneva Ixiaro Japanese encephalitis vaccine is its role in pre-travel health when planning longer stays, frequent trips, or outdoor activities such as farming or camping in rural areas of endemic countries, where mosquito exposure is higher CDC Yellow Book, 01/10/2024.

Travel medicine clinics in the United States often consider this vaccine for adults, teenagers, and sometimes children when they will spend extended time in fields, rice paddies, or small villages in high-risk regions, especially during the transmission season CDC, 03/05/2025.

US-based tour operators and corporate travel programs that send staff to Asia may include Japanese encephalitis vaccination in their occupational health protocols for employees whose work includes prolonged outdoor exposure in endemic areas CDC, 11/18/2024.

Valneva Ixiaro Japanese encephalitis vaccine in the US and global market

In the United States, Ixiaro is an FDA-licensed Japanese encephalitis vaccine for use in travelers and laboratory workers who may be exposed to Japanese encephalitis virus, available on prescription through physicians and dedicated travel health providers FDA, 03/30/2024.

Globally, public health agencies in non-endemic regions recognize the vaccine as an option for travelers to affected areas, while in endemic countries, Japanese encephalitis control focuses more on pediatric immunization programs with locally used vaccines and mosquito control measures WHO, 07/12/2024.

The market for Japanese encephalitis vaccination is closely connected to trends in international tourism, business travel, and military deployment to Asia, as these groups represent an important share of demand for travel vaccines in countries such as the United States and European states.

• Prescription travel vaccine used before trips to Japanese encephalitis risk areas.
• Inactivated formulation given as an intramuscular injection.
• Relevant mainly for longer or higher-risk stays in rural parts of Asia and the Western Pacific.
• Accessed through US travel clinics, primary care, or occupational health providers.

Frequently Asked Questions About Valneva Ixiaro Japanese encephalitis vaccine

Who should consider Valneva Ixiaro Japanese encephalitis vaccine before travel?
US travelers planning to spend extended time in rural or agricultural areas in countries where Japanese encephalitis is present, especially during mosquito season, are typical candidates.

Is Japanese encephalitis vaccination part of routine shots in the United States?
Japanese encephalitis vaccination is not a routine US childhood or adult immunization and is mainly used for travelers and some laboratory or field workers who face exposure risk.

Where can US travelers get Valneva Ixiaro Japanese encephalitis vaccine?
Travelers usually receive the vaccine at dedicated travel medicine clinics, some larger primary care practices, and occupational health centers that stock travel vaccines.

Valneva, headquartered in Europe, develops and markets Valneva Ixiaro Japanese encephalitis vaccine as part of its travel vaccines portfolio for travelers and certain professional groups.

The companys stock is associated with the ISIN FR0013280286 and is traded in European markets in the context of the broader vaccines and biotechnology sector.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.